Clinical and Biological Signature of Osteochondritis Dissecans in a Cross-Sectional Study

Elena Gabusi,1 Cristina Manferdini,1 Francesca Paolella,1 Laura Gambari,2 Elizaveta Kon,3,4 Giuseppe Filardo5, Erminia Mariani,1,6 and Gina Lisignoli1

1SCLaboratorio di Immunoreumatologia e Rigenerazione Tissutale, Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy
2Laboratorio RAMSES, Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy
3Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, Rozzano, 20089 Milan, Italy
4Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
5Clinica Ortopedica e Traumatologica I, Laboratorio NABI, Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy
6DIMEC, Alma Mater Studiorum Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy

Correspondence should be addressed to Gina Lisignoli; gina.lisignoli@ior.it

Received 30 November 2017; Accepted 24 April 2018; Published 28 May 2018

1. Introduction

Osteochondritis dissecans (OCD) of the joints has been recently defined as a focal idiopathic alteration of subchondral bone which may cause progressive changes in articular cartilage with partial or complete osteochondral detachment [1]. OCD includes two populations of patients: the juvenile form in young adolescent with open physes and the adult form in older adolescent and adults with closed physes [2, 3]. Although its original description dates back to 1887 by Konig, many questions regarding etiology, treatments, and histology remain undefined. Depending on the size of the lesions (<2 cm or >2 cm), OCD is treated using different surgical techniques such as microfractures, osteochondral autografts, and osteochondral allografts or using biomaterials with variable success rate [4, 5].

Different authors have reported that subchondral bone is involved in the etiopathological process of OCD. However, a detailed review on histological and immunohistochemical analysis of OCD fragments [6–9] found that OCD knee histological studies had variable findings and the theory of etiology was based only on a limited and not standardized research in this field. Until now, deep knowledge on OCD etiology has been limited by the considerable variation in the analytic histological techniques used in different studies [9–11]. To shed some light into the healing potential of OCD
lesions, an accurate focus on local markers and systemic serum biomarkers of cartilage and bone remodeling, as well as patients’ characteristics, is necessary and it could be the basis for better targeting and improving of current OCD therapies [12, 13].

Typical immunohistochemical markers of cartilage and bone remodeling are CD146, CD166, tartrate-resistant acid phosphatase (TRAP), and CD34. CD146 and CD166 are markers used to identify the subpopulation of MSCs progenitor cells located in bone [14] and cartilage [15, 16]. TRAP is a marker used to evaluate how cells participate in the resorption of cartilage matrix or mineralized bone matrix and it is highly expressed in polynucleated osteoclasts and chondroclasts [17], while CD34 is used as marker of endothelial cells for evaluating vascularization: these parameters are directly associated with tissue remodeling.

Among systemic biomarkers of tissue remodeling, C-telopeptide fragments of type II collagen (CTX-II) and collagenase-cleaved fragments of type II collagen (C2C) are widely used as predictive biomarkers of joint degeneration in osteoarthritis (OA). These are often associated with carboxy-terminal propeptide of type II collagen (CPII), a marker of cartilage synthesis, and TRAP5b, a marker of osteoclast activity in bone [18, 19]. Recently, CTX-II has also been investigated [20] in patients with focal cartilage lesion of the knee who showed a higher level compared to healthy subjects.

The aim of this study was to combine, in a cross-sectional study, the evaluation of both local and systemic biomarkers of cartilage and bone remodeling and to associate them with OCD patient characteristics in order to have a more complete picture of this pathology, which could shed some light on the healing potential of OCD lesions.

2. Materials and Methods

2.1. Patient Characteristics. The OCD patients (N = 16) included in the study presented focal lesions (at least 1.5 cm² and less than 4 cm²) of the articular surface in otherwise healthy joints (no evidence of other chondral-osteochoondral, ligament, meniscus, or synovial lesions), with stable and physiologically aligned knees. X-Ray and MRI surgical indication were confirmed intra-articularly, and patients were staged as grade 3 OCD lesions, according to the ICRS evaluation package [https://www.secot.es/uploads/descargas/valoracion/ICRS_TRUMA_CARTLAGO.pdf], which includes the International Knee Documentation Committee (IKDC). Knee Examination Form 2000 was administered to assess symptoms and function in daily living activities. This questionnaire looks at 3 categories: symptoms, sports activity, and knee functionality. Scores are obtained by adding up the individual items and then transforming the crude total to a scaled number that ranges from 0 to 100 (representing no symptoms and no limitations with daily activities). The characteristics of each patient included in the study are summarized in Table 1.

OCD lesions were intraoperatively found to be unsuitable for fragment refixation; therefore the injured area was removed and evaluated for this current cross-sectional study, while the defect was reconstructed with the implantation of an osteochondral scaffold. The study was approved by the local ethical committee and, prior to inclusion, all patients signed a written informed consent form.

2.2. Histochemical Analysis and Scoring. Osteochondral fragments were fixed in a freshly prepared 9:1 mixture of B5 solution (mercuric-chloride containing fixative)/40% formaldehyde and embedded in paraffin and both cartilage and bone tissues were scored as previously described [21]. Briefly, at least 5 serial sections from each osteochondral fragment were stained with Safranin O fast green and both cartilage and bone tissues were histologically scored by two readers (Elena Gabusi and Gina Lisignoli). The maximum cartilage and bone scores were 16 and 10 (highly degenerated tissue), respectively, while normal tissue was scored 0.

2.3. Immunohistochemical Analysis. Histological sections were deparaffinized and incubated at room temperature for 1 hour with the following monoclonal mouse anti-human antibodies: CD146 (clone N1238, Novocastra, Leica Biosystems, Newcastle, UK), CD166 (clone MOG/07, Abcam, Cambridge, UK), TRAP (clone 26E5, Novocastra), or CD34 (clone QBEnd, DakoCytomation, Glostrup, Denmark) diluted in TBS containing 0.25% BSA and 0.1% NaNO₃. Negative controls were performed by omitting the primary antibody, and isotype-matched controls were performed by using an isotype-matched primary antibody.

Semiquantitative analysis of immunohistochemistry stained slides was performed on 15 microscopic fields (20x objective lens) for each section. The analysis was performed using Red/Green/Blue (RGB) with Software NIS-Elements and Eclipse 90i microscope (Nikon Instruments Europe BV) equipped with a CCD camera (dimension of the sensor: 2/3 inches) mounted on 0.7x C-mount. Briefly, we acquired the total number of blue-stained nuclei and the total number of positive-stained red cells in each field (358 x 269.15 µm). Data were expressed as a mean percentage of positive cells for CD146, CD166, and TRAP, respectively. The number of positive CD34 vessels was counted manually and expressed as the mean number of vessels/area. All data obtained from

| Table 1: OCD patients’ characteristics. |
|----------------------------------------|
| Patients (n.) | 16 |
| Lesion location | 1 Trochlea, 2 LFC, 13 MFC |
| Sex | 4 Females, 12 Males |
| IKDC clinical score | 55.5 ± 13.4* |
| Age | 23 ± 8.3* |
| BMI | 24 ± 3.9* |
| Physes | 1 open, 15 closed |

LFC: lateral femoral condyle, MFC: medial femoral condyle, IKDC: international knee documentation committee, BMI: body mass index. * Mean ± SD.
each fragment/section were then expressed as median and 10–90 percentiles.

2.4. Biomarkers of Cartilage and Bone Remodeling. On the same day of surgery, a serum sample was collected from each patient. The following serum biomarkers of cartilage remodeling were analyzed following the company instructions: CTX-II (Elabscience Biotechnology Co., Ltd., Wuhan, Hubei Province, China), C2C (IBEX Pharmaceutical Inc., Montréal, Québec, Canada), CPII (IBEX Pharmaceutical Inc., Montréal, Québec, Canada), and bone remodeling TRAP5b (Quidel Corporation, Athens, OH, USA). Control healthy subjects (N = 8) were also evaluated. Data were expressed for all assays as ng/ml, except TRAP5b that was expressed in U/ml.

2.5. Statistical Analysis. The normal distribution of continuous data was analyzed with Kolmogorov-Smirnov test and since data were not normal, we used nonparametric tests. Statistical analysis for comparing cartilage and bone was performed with Mann–Whitney U test for unpaired two-group data. Spearman correlations were evaluated between clinical (IKDC subjective score) and biological (cartilage score or bone score or immunohistochemical markers or serum biomarkers) markers. We performed multivariate analysis using the Generalized Linear Model (GLM) based on gamma distribution to assess the variables that significantly and independently predicted the IKDC subjective score, and the Wald method was used for the selection of the variables. CSS Statistical Software (StatSoft Inc., Tulsa, OK, USA) was used for analysis. All results were considered significant for p < 0.05.

3. Results

3.1. Histological Characterization of OCD Fragments. Osteochondral fragments were obtained from 16 patients (4 females and 12 males, Table 1) with lesions mainly in the medial femoral condyle (81.3%). Safranin O-stained sections evidenced that all patients showed a median cartilage score of 9 (25th percentile = 5.5 and 75th percentile = 10) with a maximal score equal to 16 (Figure I(a)), while bone score
showed a median of 6 (25th percentile = 4 and 75th percentile = 8) with a maximal score equal to 10 (Figure 1(b)).

3.2. Cartilage Tissue Score Correlated with Patient IKDC Subjective Score. Further analysis was performed to determine if cartilage and bone tissue scores were correlated with the patient’s characteristics (IKDC subjective score, age, and BMI). We found that only cartilage tissue score was significantly correlated (Rho = 0.412; \( p = 0.05 \)) with the IKDC subjective score (Figure 1(c)), while there was no correlation with bone score (Figure 1(d)). No correlation was also found with age or BMI (data not shown).

3.3. Different Levels of Systemic Biomarkers in OCD Compared to Healthy Subjects. Systemic biomarkers of cartilage degradation (CTX-II and C2C) or synthesis (CPII) and bone remodeling (TRAP5b) were measured in OCD patients and compared to healthy subjects. We found that CTX-II was significantly higher in OCD (\( p = 0.0035 \)) compared to healthy subjects, while C2C, CPII, and TRAP5b were significantly decreased in OCD (\( p = 0.0005 \), \( p = 0.0001 \), and \( p = 0.012 \), resp.) compared to healthy subjects (Figure 2). We therefore investigated whether these biomarkers of cartilage and bone remodeling were associated with the patients characteristics (IKDC subjective score, age, and BMI).

3.4. Cartilage and Bone Tissue Scores Differently Correlated with Serum Biomarkers. The correlation of both cartilage and bone tissue scores with these biomarkers evidenced a significant inverse correlation only for C2C (Rho = 0.582; \( p = 0.009 \)) and CPII (Rho = 0.528; \( p = 0.02 \)) with cartilage tissue score (Figure 3(a)), showing lower levels of these biomarkers in patients with higher degraded cartilage. Interestingly, no correlation was found with CTX-II or cartilage biomarkers ratios (C2C/CPII and CTX-II/CPII) or TRAP5b biomarkers (data not shown). By contrast, bone tissue score showed a significant inverse correlation with CPII (Rho = −0.491; \( p = 0.033 \)) and a direct correlation with C2C/CPII ratio (Rho = 0.581; \( p = 0.009 \)) (Figure 3(b)) but it was not correlated with bone degradation biomarker TRAP5b or with CTX-II and C2C.

3.5. Immunohistochemical Markers of Tissue Remodeling Were Highly Expressed in Bone. To define osteochondral tissue remodeling in OCD fragments, we evaluated the following markers with immunohistochemistry in both cartilage and bone tissues: CD146, CD166, CD34, and TRAP. As shown in Figure 4, all tested markers showed a significantly (CD146 and CD166, \( p = 0.0001 \)) higher percentage of positive cells located mainly in bone rather than in cartilage.

Figure 2: Serum biomarkers evaluation in OCD and healthy subjects. Biomarkers of cartilage degradation (CTX-II and C2C), synthesis (CPII), and bone remodeling (TRAP5b) are represented as box plot with median and 25th and 75th interquartile ranges. CTX-II, C2C, and CPII were expressed as ng/ml, while TRAP5b is expressed as U/ml.
3.6. CD146, CD166, CD34, and TRAP Tissue Markers Were Differently Correlated with Histological Scores and Serum Biomarkers. We also investigated whether CD146, CD166, CD34, and TRAP were linked to cartilage and bone scores or to cartilage and bone remodeling biomarkers. As shown in Table 2, an inverse correlation between percentage of cartilage cells positive to CD146 and CD166 and cartilage score was observed. Interestingly, a direct correlation with both degradation (CTX-II and C2C) and synthetic (CPII) cartilage biomarkers was found with the percentage of CD146 cells. By contrast, the percentage of CD166 positive cells in cartilage was inversely correlated with both CTX-II and C2C.

The percentage of TRAP positive cells in bone was directly correlated with the bone score (Rho = 0.125; p = 0.039).

3.7. Immunohistochemical Markers of Cartilage and Bone Remodeling Were Differently Correlated with the Patients’ Characteristics. We correlated all cartilage and bone remodeling immunohistochemical markers with IKDC subjective score, age, and BMI. As shown in Table 3, the percentage of CD146 in cartilage and the percentage of CD34 in bone were indirectly correlated with age and BMI, respectively. Interestingly, the percentage of TRAP in bone was directly correlated with both IKDC subjective score and age.

3.8. Specific Systemic and Local Markers as a Model to Predict IKDC Subjective Score. To define which of the significant biological markers (cartilage score, bone score, percentage of CD146 and CD166 in cartilage, percentage of CD34 in cartilage or bone, percentage of TRAP in bone, CTX-II,
Figure 4: Immunohistochemical analysis of CD146, CD166, CD34, and TRAP on cartilage and bone tissues. Each point represents the analysis performed in each field of the analyzed section. CD146, CD166, and TRAP are expressed as percentage of positive cells; CD34 is expressed as number of positive vessels.

Table 3: Correlations between percentage of CD146, CD166, and CD34 in bone and cartilage and patients characteristics.

|                  | % CD146 in cartilage | % CD34 in bone | % TRAP in bone |
|------------------|-----------------------|----------------|----------------|
|                  | Rho       | p      | Rho       | p      | Rho       | p      |
| IKDC score       | −0.054    | 0.470  | −0.002    | 0.976  | 0.191     | <0.0005|
| Age              | −0.420    | <0.0005| 0.063     | 0.317  | 0.191     | <0.0005|
| BMI              | −0.157    | 0.082  | −0.270    | <0.0005| 0.095     | 0.082  |

C2C, CPII, TRAP5b, C2C/CPII, and CTX-II/CPII), analyzed by Spearman correlation, was the best predictor of IKDC subjective score, the multivariate GLM test was performed. As shown in Figure 5(a), we found that only cartilage and bone score together with CTX-II and TRAP5b were biological markers that significantly and independently predicted IKDC subjective score. In particular, the predicted values, calculated using the GLM model results (Figure 5(a)), had a high correlation with the IKDC subjective score ($r = 0.729; p < 0.0005$) (Figure 5(b)).

4. Discussion

OCD of the knee is a common and poorly understood pediatric and adult condition. Decision regarding different surgical treatments remains unsupported by current literature [1, 12, 13]. We concentrated on focal OCD of the knee by performing a cross-sectional study that took into consideration local markers as well as systemic cartilage and bone remodeling biomarkers to assess whether the healing potential was correlated with the patient characteristics (IKDC subjective score, age, and BMI).

Firstly, we confirmed that OCD bone tissue, as recently published [21], showed a higher median histological score compared to cartilage, indicative of active tissue remodeling. The OCD cartilage median score also well reflected the modifications of this tissue and suggested that the focal degeneration of the cartilage matrix could originate from subchondral bone. This observation, based on the use of specific scores for cartilage and bone tissue, has also been confirmed in other previous studies [9, 11].
Moreover, a higher number of cells positive for remodeling markers (CD146, CD166, TRAP, and CD34) have been found in bone than in cartilage, confirming active bone remodeling as previously reported by some histological studies [10] and our recent paper [21]. Histological and immunohistochemical results clearly support the recent definition of OCD as “focal, idiopathic alteration of subchondral bone with risk for instability and disruption of adjacent articular cartilage” [22].

We found that bone histological score is directly correlated only with the percentage of TRAP, a specific enzyme produced by osteoclasts [23]. TRAP was also directly correlated with both IKDC subjective score and age (Table 3), confirming high bone remodeling activity in OCD patients. In fact, it is well known that age plays a decisive role in OCD development and it is important for its prognosis [24]. Moreover, we have also demonstrated that the percentage of CD34 (marker of vascularization) positive cells in bone was significantly negatively correlated with BMI, indicating a lower number of vessels in obese patients, which might suggest a different pathway of bone tissue remodeling.

It is well known that the percentage of markers of cartilage derived mesenchymal stem cells (CD146 and CD166) significantly decreases in worst histological cartilage score and our data also confirmed lower remodeling of cartilage tissue [15, 16]. In particular, although the decrease of CD146 percentage did not reach a significant correlation with cartilage score (p = 0.59), data showed a correlation with aging, confirming that cartilage remodeling is also strictly dependent on the age of the patients. Interestingly, the percentage of CD146 positive cells increased with both biomarkers of cartilage degradation (CTX-II and C2C) and synthesis (CPII), while CD166 was inversely correlated, indicating that the active process of cartilage remodeling was also influenced by systemic factors. It has been shown that these serum systemic biomarkers are good surrogates because they reflect the concentrations observed in the synovial fluid from the knee [25]. We have found that systemic biomarkers C2C and CPII are both significantly and inversely correlated with cartilage score, indicating that worst histological characteristics of this tissue corresponded to lower levels of both biomarkers of cartilage degradation and synthesis. It has been shown that CTX-II is correlated with histological Mankin score in osteoarthritis animal model [19] and with severity of knee OA [26]. However, we could not find any correlation between CTX-II biomarkers and cartilage score, although this biomarker could be considered a good indicator of cartilage degradation [25]. Interestingly, Røtterud et al. [20, 23] included in their study both traumatic and OCD patients and correlated CTX-II biomarker with the patients’ characteristics. By contrast, our study has focused only on OCD patients and has considered at the same time both local (histological score and immunohistochemical markers) and systemic serum biomarkers to have a complete picture of this disease. Moreover, in line with previously published data [20], we detected CTX-II as the only biomarker in higher amount in OCD patients compared to healthy subjects.

We have found that CPII and C2C/CPII ratio, good indicators of collagen type II synthesis and degradation, are also, respectively, negatively and positively correlated to bone histological score. These data indicate that their levels are associated with worst bone histology with a clear decrease of the synthetic CPII biomarker and an increase of C2C/CPII ratio, confirming the presence of concomitant bone and cartilage remodeling in OCD patients.

The IKDC subjective score is used by clinicians to assess symptoms and functionality in daily living activities: we have found that it is significantly correlated only with cartilage

| Biological markers | Slope | 95% confidence interval of slope | p value |
|-------------------|-------|---------------------------------|---------|
| Intercept         | 46.932| 39.616                          | 54.248  |
| CTX-II            | 0.002 | 0.001                           | 0.003   |
| TRAP5b            | −4.642| −5.193                          | −4.092  |
| Cartilage score   | 0.931 | 0.502                           | 1.359   |
| Bone score        | −0.601| −1.059                          | −0.143  |

|                |        |                                | p value |
|----------------|--------|---------------------------------|---------|
| Intercept      | 46.932 | 39.616                          | 54.248  | <0.0005 |
| CTX-II         | 0.002  | 0.001                           | 0.003   | <0.0005 |
| TRAP5b         | −4.642 | −5.193                          | −4.092  | <0.0005 |
| Cartilage score| 0.931  | 0.502                           | 1.359   | <0.0005 |
| Bone score     | −0.601 | −1.059                          | −0.143  | 0.01    |

**Figure 5: IKDC subjective score prediction.** (a) GLM model results evidence that four of the analyzed parameters (CTX-II, TRAP5b, cartilage score, and bone score) are good predictors of IKDC subjective score. (b) Correlation between IKDC subjective score and predicted IKDC subjective score ($R = 0.729; p < 0.0005$). Each point represents the value of IKDC subjective score and its predicted value calculated on GLM model results.
histological score, indicating that in OCD patients (with focal lesions) a better clinical score does not directly correspond to a good histological characteristic of cartilage. This result might suggest that histological signs of cartilage damage occur before the onset of clinical symptoms.

Finally, we have used a GLM model to define which of the analyzed biological markers should be good parameters to estimate the IKDC subjective score and the model has evidenced that only four (histological cartilage and bone scores, CTX-II, and TRAP5b) were good independent predictors. Interestingly, two of them are local (histological cartilage and bone scores) and two are systemic (CTX-II and TRAP5b) biological markers, specific of cartilage or bone, respectively, confirming again that this disease is dependent on balanced remodeling of both bone and cartilage tissues. This GLM model has strongly established a direct link between the four predictors and the IKDC subjective score, suggesting that this could also be a useful predictive tool during the clinical follow-up. However, this hypothesis must be confirmed in a future longitudinal study.

5. Conclusions
In conclusion, this study gives an overall picture of knee OCD focal lesions, since we have considered both local and systemic markers of bone and cartilage remodeling and combined them with patients’ characteristics to assess their healing potential. These data have allowed us to develop a good GLM predictor model, which might help to better focus on and improve currently used focal knee OCD therapies.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments
This work was supported by a grant from “Regione Emilia-Romagna PRRU 2010–2012 project: Regenerative Medicine of Cartilage and Bone.”

References
[1] J. Bruns, M. Werner, and C. Habermann, “Osteochondritis dissecans: etiology, pathology, and imaging with a special focus on the knee joint,” Cartilage, pp. 1–17, 2017.
[2] B. Cahill, “Treatment of juvenile osteochondritis dissecans and osteochondritis dissecans of the knee,” Clinics in Sports Medicine, vol. 4, no. 2, pp. 367–384, 1985.
[3] W. T. Green and H. H. Banks, “Osteochondritis dissecans in children,” The Journal of Bone & Joint Surgery—American volume, vol. 35, no. 1, pp. 26–64, 1953.
[4] G. Zamon, G. Di Vico, and M. Marullo, “Osteochondritis dissecans of the talus,” Joints, vol. 2, no. 3, pp. 115–123, 2017.
[5] N. Stadler and K. Trieb, “Osteochondritis dissecans of the medial femoral condyle: New cell-free scaffold as a treatment option,” Der Orthopäde, vol. 45, no. 8, pp. 701–705, 2016.
[6] K. G. Shea, J. C. Jacobs Jr., J. L. Carey, A. F. Anderson, and J. T. Oxford, “Osteochondritis dissecans knee histology studies have variable findings and theories of etiology,” Clinical Orthopaedics and Related Research, vol. 471, no. 4, pp. 1127–1136, 2013.
[7] B. Lindén and H. Telhag, “Osteochondritis dissecans: A histologic and autoradiographic study in man,” Acta Orthopaedica, vol. 48, no. 6, pp. 682–686, 1977.
[8] Y. Yonetani, N. Nakamura, T. Natsuume, Y. Shiozaki, Y. Tanaka, and S. Horibe, “Histological evaluation of juvenile osteochondritis dissecans of the knee: A case series,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 18, no. 6, pp. 723–730, 2010.
[9] S. Koch, W. U. Kampen, and H. Laprell, “Cartilage and bone morphology in osteochondritis dissecans,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 5, no. 1, pp. 42–45, 1997.
[10] H. Uozumi, T. Sugita, T. Aizawa, A. Takahashi, M. Ohnuma, and E. Itoi, “Histologic findings and possible causes of osteochondritis dissecans of the knee,” The American Journal of Sports Medicine, vol. 37, no. 10, pp. 2003–2008, 2009.
[11] M. Aurich, J. Anders, T. Trommer et al., “Histological and cell biological characterization of dissected cartilage fragments in human osteochondritis dissecans of the femoral condyle,” Archives of Orthopaedic and Trauma Surgery, vol. 126, no. 9, pp. 606–614, 2006.
[12] D. L. Richter, R. C. Schenck Jr., D. C. Wascher, and G. Treme, “Knee articular cartilage repair and restoration techniques: a review of the literature,” Sports Health, vol. 8, no. 2, pp. 153–160, 2016.
[13] A. G. McNickle, M. T. Provencher, and B. J. Cole, “Overview of existing cartilage repair technology,” Sports Medicine & Arthroscopy Review, vol. 16, no. 4, pp. 196–201, 2008.
[14] P. Bianco, “‘Mesenchymal stem cells,” Annual Review of Cell and Developmental Biology, vol. 30, no. 1, pp. 677–704, 2014.
[15] Z. Xia, P. Ma, N. Wu et al., “Altered function in cartilage derived mesenchymal stem cell leads to OA-related cartilage erosion,” American Journal of Translational Research, vol. 8, no. 2, pp. 433–446, 2016.
[16] Y. Jiang, Y. Cai, W. Zhang et al., “Human cartilage-derived progenitor cells from committed chondrocytes for efficient cartilage repair and regeneration,” Stem Cells Translational Medicine, vol. 5, no. 6, pp. 733–744, 2016.
[17] H. J. Knowles, L. Moskovsky, M. S. Thompson et al., “Chondroclasts are mature osteoclasts which are capable of cartilage matrix resorption,” Virchows Archiv, vol. 461, no. 2, pp. 205–210, 2012.
[18] L. T. Nguyen, A. R. Sharma, C. Chakraborty, S. Bababa, M. E. Ahn, and S. S. Lee, “Review of prospects of biological fluid biomarkers in osteoarthritis,” International Journal of Molecular Sciences, vol. 18, no. 3, p. 601, 2017.
[19] C. H. Coyle, S. E. Henry, A. M. Haleem, M. J. O’Malley, and C. R. Chu, “Serum CTXII correlates with articular cartilage degeneration after anterior cruciate ligament transection or arthrootomy followed by standardized exercise,” Sports Health, vol. 4, no. 6, pp. 510–517, 2012.
[20] J. H. Rotterud, F. P. Reinhold, K. J. Beckstrom, M. A. Risberg, and A. Ågren, “Relationship between CTX-II and patient characteristics, patient-reported outcome, muscle strength, and rehabilitation in patients with a focal cartilage lesion of the knee: a prospective exploratory cohort study of 48 patients,” BMC Musculoskeletal Disorders, vol. 15, no. 1, article 99, 2014.
[21] E. Gabusi, C. Manfredini, F. Paolella et al., “Focal defects of the knee articular surface: evidence of a regenerative potential option,” Cartilage and Bone.”
pattern in osteochondritis dissecans and degenerative lesions,” BioMed Research International, vol. 2017, Article ID 9036305, 9 pages, 2017.

[22] E. W. Edmonds and K. G. Shea, “Osteochondritis dissecans: editorial comment,” Clinical Orthopaedics and Related Research, vol. 471, no. 4, pp. 1105-1106, 2013.

[23] J. M. Halleen, S. L. Alatalo, A. J. Janckila, H. W. Woitge, M. J. Seibel, and H. K. Vaananen, “Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption,” Clinical Chemistry, vol. 47, no. 3, pp. 597–600, 2001.

[24] J. W. Michael, A. Wurth, P. Eysel, and D. P. König, “Long-term results after operative treatment of osteochondritis dissecans of the knee joint—30 year results,” International Orthopaedics, vol. 32, no. 2, pp. 217–221, 2008.

[25] J. B. Catterall, T. V. Stabler, C. R. Flannery, and V. B. Kraus, “Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254),” Arthritis Research & Therapy, vol. 12, no. 6, article R229, 2010.

[26] J. Kumm, A. Tamm, M. Lintrop, and A. Tamm, “The value of cartilage biomarkers in progressive knee osteoarthritis: cross-sectional and 6-year follow-up study in middle-aged subjects,” Rheumatology International, vol. 33, no. 4, pp. 903–911, 2013.